PCNA [Proliferation Marker] Antibody, PerCP Conjugated
Référence bs-2007R-PerCP
Conditionnement : 100ul
Marque : Bioss
PCNA [Proliferation Marker] Antibody, PerCP Conjugated
Applications
Reactivity
Predicted Reactivity
Overview | |
Catalog # | bs-2007R-PerCP |
Product Name | PCNA [Proliferation Marker] Antibody, PerCP Conjugated |
Applications | WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Reactivity | Human, Mouse, Rat, Chicken |
Predicted Reactivity | Dog, Cow, Rabbit |
Specifications | |
Conjugation | PerCP |
Host | Rabbit |
Source | KLH conjugated synthetic peptide derived from human PCNA |
Immunogen Range | 201-261/261 |
Clonality | Polyclonal |
Isotype | IgG |
Concentration | 1ug/ul |
Purification | Purified by Protein A. |
Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target | |
Gene ID | 5111 |
Swiss Prot | P12004 |
Subcellular location | Nucleus |
Synonyms | ATLD2; Proliferating cell nuclear antigen; PCNA; Cyclin |
Background | Auxiliary protein of DNA polymerase delta and is involved in the control of eukaryotic DNA replication by increasing the polymerase's processibility during elongation of the leading strand. Induces a robust stimulatory effect on the 3'-5' exonuclease and 3'-phosphodiesterase, but not apurinic-apyrimidinic (AP) endonuclease, APEX2 activities. Has to be loaded onto DNA in order to be able to stimulate APEX2. Plays a key role in DNA damage response (DDR) by being conveniently positioned at the replication fork to coordinate DNA replication with DNA repair and DNA damage tolerance pathways. Acts as a loading platform to recruit DDR proteins that allow completion of DNA replication after DNA damage and promote postreplication repair: Monoubiquitinated PCNA leads to recruitment of translesion (TLS) polymerases, while 'Lys-63'-linked polyubiquitination of PCNA is involved in error-free pathway and employs recombination mechanisms to synthesize across the lesion. |
Application Dilution | |
WB | 1:300-5000 |
FCM | 1:20-100 |
IF(IHC-P) | 1:50-200 |
IF(IHC-F) | 1:50-200 |
IF(ICC) | 1:50-200 |